Inventiva Sa (IVA) Peer Comparison
$4.90
$0.08
(1.66%)
As on 27-Aug-2026 16:00EDT
Market cap
$1,106 Mln
Revenue (TTM)
$39 Mln
P/E Ratio
--
P/B Ratio
2.1
Div. Yield
0 %
Edit
| Inventiva Sa (IVA) | Nanobiotix (NBTX) | Galapagos NV - ADR | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
1,106 | 2,213 | 1,862 | 660 | 252 |
Revenue (€ Mln) |
4 | 30 | 1,044 | 144 | 3 |
Net Profit (€ Mln) |
-340.16 | -23.96 | 488.78 | -158.17 | -49.18 |
Net Margin (%) |
-540.52 | -- | 46.83 | -110.21 | -72.76 |
RoE (%) |
501.41 | 31.91 | 15.95 | -168.93 | 764.76 |
Price to Earnings |
-- | -- | 3.18 | -- | -- |
Price-To-Book |
2.10 | 65.02 | 0.49 | 6.89 | 20.10 |
Income Statement (€ Mln)
| Inventiva Sa (IVA) | Nanobiotix (NBTX) | Galapagos NV - ADR | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4.48 | 29.64 | 1,112.25 | 174.66 | 2.79 |
|
Cost of Revenue
|
2.80 | -- | 29.74 | 107.14 | -- |
|
Gross Profit
|
1.51 | 29.64 | 1,082.51 | 67.52 | 2.79 |
|
Operating Expenses
|
137.37 | 40.46 | 581.12 | 149.15 | 56.21 |
|
Operating Profit (EBIT)
|
-130.95 | -10.82 | 501.39 | -81.63 | -53.43 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-342.33 | -23.96 | 300.87 | -114.12 | -49.18 |
|
Provision for Tax
|
0.02 | 0.00 | -18.62 | 1.07 | -5.96 |
|
Profit after Tax (Net Income)
|
-340.16 | -23.96 | 320.88 | -115.19 | -49.18 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities (€ Mln)
| Inventiva Sa (IVA) | Nanobiotix (NBTX) | Galapagos NV - ADR | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-29.04 | -84.48 | 3,234.49 | 106.17 | -21.69 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
200.57 | 94.74 | 17.78 | 199.33 | 47.75 |
|
Current Liabilities
|
77.35 | 57.51 | 152.80 | 93.33 | 36.63 |
|
Total Liabilities
|
248.88 | 67.76 | 3,405.07 | 398.84 | 62.69 |
Assets (€ Mln)
| Inventiva Sa (IVA) | Nanobiotix (NBTX) | Galapagos NV - ADR | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
5.04 | 5.01 | 326.92 | 176.30 | 16.00 |
|
Current Assets
|
243.84 | 62.75 | 3,078.15 | 222.54 | 46.69 |
|
Total Assets
|
248.88 | 67.76 | 3,405.07 | 398.84 | 62.69 |
|
Total Debt*
|
59.40 | 95.32 | 6.92 | 207.25 | 22.56 |
|
Net Current Assets
|
167.09 | 5.24 | 2,926.59 | 129.21 | 10.06 |
Cashflow (€ Mln)
| Inventiva Sa (IVA) | Nanobiotix (NBTX) | Galapagos NV - ADR | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-100.98 | -33.42 | -189.23 | -52.89 | -32.56 |
|
Cash Flow from Investing Activities
|
-127.93 | -0.58 | 219.35 | -1.71 | 20.63 |
|
Cash from Financing Activities
|
232.00 | 37.42 | -3.14 | -0.62 | -1.97 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Inventiva Sa (IVA) | Nanobiotix (NBTX) | Galapagos NV - ADR | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
3,098.72 | 1,208.63 | 10.44 | -32.40 | -241.67 |
|
ROE (%)
|
501.41 | 31.91 | 10.47 | -80.16 | 764.76 |
|
ROA (%)
|
-184.95 | -35.45 | 8.51 | -25.63 | -56.61 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-7,587.80 | -80.83 | 28.85 | -65.95 | -1,764.51 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Inventiva Sa (IVA) | Nanobiotix (NBTX) | Galapagos NV - ADR | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.51 | 5.12 | 3.04 | 0.03 | -0.78 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-84.66 | 64.83 | 333.15 | -840.57 | 0.59 |
|
EPS Growth (%)
|
0.85 | 0.65 | 3.39 | -6.62 | 0.12 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Inventiva Sa (IVA) | Nanobiotix (NBTX) | Galapagos NV - ADR | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-8.71 | -46.14 | 6.71 | -6.64 | -3.25 |
|
Price / Book Value
|
-102.03 | -13.09 | 0.67 | 7.20 | -7.37 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-21.78 | -95.14 | -2.33 | -17.09 | -3.40 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Inventiva Sa (IVA) | Nanobiotix (NBTX) | Galapagos NV - ADR | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-2.05 | -1.13 | 0.00 | 1.95 | -1.04 |
|
Short term debt to equity ratio
|
-1.11 | -0.05 | 0.00 | 0.19 | -0.41 |
|
Current Ratio
|
3.15 | 1.09 | 20.15 | 2.38 | 1.27 |
|
Quick Ratio
|
3.15 | -- | 20.00 | 1.85 | -- |
|
Interest Coverage
|
-4.05 | -1.30 | 136.71 | -1.72 | -110.77 |
Operating Efficiency Ratios
| Inventiva Sa (IVA) | Nanobiotix (NBTX) | Galapagos NV - ADR | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
203.37 | 25.91 | 4.78 | 15.92 | 273.05 |
|
Asset Turnover
|
0.02 | 0.44 | 0.29 | 0.39 | 0.03 |
|
Receivable days
|
866.65 | 99.90 | 16.53 | 65.89 | 606.33 |
|
Inventory Days
|
0.00 | -- | 452.54 | 177.10 | -- |
|
Payable days
|
3,844.90 | -- | 1,242.94 | 37.01 | -- |
|
Cash Conversion Cycle
|
-2,978.25 | -- | -773.87 | 205.98 | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
